Advertisement
Canada markets closed

  • S&P/TSX

    22,007.00
    -222.10 (-1.00%)
     

  • S&P 500

    5,346.99
    -5.97 (-0.11%)
     

  • DOW

    38,798.99
    -87.18 (-0.22%)
     

  • CAD/USD

    0.7265
    -0.0051 (-0.70%)
     

  • CRUDE OIL

    75.28
    -0.27 (-0.36%)
     

  • Bitcoin CAD

    95,245.93
    -2,016.28 (-2.07%)
     

  • CMC Crypto 200

    1,437.27
    -41.44 (-2.80%)
     

  • GOLD FUTURES

    2,308.80
    -82.10 (-3.43%)
     

  • RUSSELL 2000

    2,026.55
    -22.89 (-1.12%)
     

  • 10-Yr Bond

    4.4300
    +0.1490 (+3.48%)
     

  • NASDAQ

    17,133.12
    -40.00 (-0.23%)
     

  • VOLATILITY

    12.22
    -0.36 (-2.86%)
     

  • FTSE

    8,245.37
    -39.97 (-0.48%)
     

  • NIKKEI 225

    38,683.93
    -19.58 (-0.05%)
     

  • CAD/EUR

    0.6723
    +0.0009 (+0.13%)
     
MARKETS LIVE BLOG:

U.S. STOCKS DIP ON UNEXPECTED JOBS STRENGTH BUT NOTCH WEEKLY WINS

GameStop sinks 40% as 'Roaring Kitty' livestream fails to revive stock

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Business Wire
·1 min read

REDWOOD CITY, Calif. & BOSTON, May 14, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.

Details of the poster presentation are as follows:

Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Presenting Author: Yvan Chanthery, Ph.D.
Date & Time: June 14, 2024 at 18:00 CEST

ADVERTISEMENT

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514346504/en/

Contacts

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com